Abstract 4498
Background
Patients’ involvement in the health technology assessment (HTA) decision-making process is important for transparency, legitimacy and fairness. The study objectives were to understand breast cancer patients’ perspectives when choosing their treatment, highlight treatment characteristics valued as most important by patients and gain information on patients’ trade-offs between available treatments.
Methods
A discrete choice experiment survey of breast cancer patients was conducted in Spain, Poland, France and Ireland. The survey design included: literature review, qualitative research, cognitive debriefing, data collection and analysis. A panel of experts from participating countries (physicians, patient group representatives, ex-payers) selected the survey treatment attributes: progression-free survival (PFS), febrile neutropenia (FN), pain, functional well-being (FWB) and out-of-pocket payment (OPP). Patients selected (or opted-out) between two unlabelled hypothetical treatments containing the previously mentioned five attributes. Panels of breast cancer patients were recruited as respondents and the questionnaire was deployed through a website platform. A D-efficient experimental design with 16 choice-sets was constructed and a conditional logistic model was used to estimate patients’ preferences. Marginal rates of substitution (MRS) was used to estimate out-of-pocket payments.
Results
In total, 317 breast cancer patients completed the survey. FWB and pain were the most important attributes chosen by patients. Respondents were willing to pay €17,288 out-of-pocket to move from severe to no impairment in FWB, followed by moderate impairment (€15,297) and from severe pain to no pain state (€15,138). Patients would pay €574 annually for one additional PFS month. Preferences differed by age for FN and FWB; highly educated patients have stronger preference for PFS compared to non-highly educated.
Conclusions
Breast cancer treatments that improve pain, FWB and PFS are considered preferred treatments from patients’ perspective.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novartis Oncology Region Europe.
Funding
Novartis Oncology Region Europe.
Disclosure
T. Konstantopoulou: Full / Part-time employment: Novartis Oncology. E. Stamuli: Research grant / Funding (institution): Novartis Oncology Region Europe. D. Ross: Advisory / Consultancy: Novartis Oncology Region Europe. R. Pacheco: Full / Part-time employment: Novartis Oncology Region Europe.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract